Search - tctmd.com

Displaying 341 - 360 of 1385

Sort: Relevancy | Date

Presentation TCT 2016

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Presenter: Maurice Buchbinder, Horst Sievert, C. Huie Lin

October 31, 2016

Presentation TCT 2016

Transcatheter Mitral Valve Repair With MitraClip for Severe Functional Mitral Insufficiency After Heart Transplant

Presenter: Danny Dvir, Marco Moscarelli, Caterina Gandolfo

October 31, 2016

Presentation TCT 2016

Severe AS and COPD

Presenter: Howard C. Herrmann, Vinod H. Thourani, Kendra J. Grubb

October 31, 2016

Presentation TCT 2016

Low-gradient AS Diagnosis and Management

Presenter: Howard C. Herrmann, Vinod H. Thourani, Allan Schwartz

October 31, 2016

Presentation TCT 2016

Severe AS With a Small Aortic Annulus

Presenter: Howard C. Herrmann, Vinod H. Thourani, Josep Rodés-Cabau

October 31, 2016

Presentation TCT 2016

Severe AS and LV Dysfunction

Presenter: Howard C. Herrmann, Vinod H. Thourani, G. Michael Deeb

October 31, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research V: Updates From U.S. TVT Registry Newest Findings

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, John D. Carroll

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research IV: Updates From FRANCE 2 Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Helene Eltchaninoff

October 30, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Clinical Updates

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Danny Dvir

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Corrado Tamburino

October 30, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? Stop Wasting Valuable Time Go Straight to LVAD/Transplant!

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Nir Uriel

October 30, 2016

Presentation TCT 2016

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Engineering Perspectives

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Neil E. Moat

October 30, 2016

Presentation TCT 2016

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? MitraClip Should Always Be Considered First!

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Saibal Kar

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Thomas Walther

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Presenter: A. Pieter Kappetein, Allan Schwartz, James B. Hermiller Jr.

October 30, 2016

Advertisement

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Transcatheter Mitral Valve Repair With MitraClip for Severe Functional Mitral Insufficiency After Heart Transplant

Severe AS and COPD

Low-gradient AS Diagnosis and Management

Severe AS With a Small Aortic Annulus

Severe AS and LV Dysfunction

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Key Contributions to TAVR Clinical Research V: Updates From U.S. TVT Registry Newest Findings

Key Contributions to TAVR Clinical Research IV: Updates From FRANCE 2 Registry

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Clinical Updates

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? Stop Wasting Valuable Time Go Straight to LVAD/Transplant!

Valve-in-Valve Therapies - Not Just a Russian Doll! Technical and Clinical Challenges: Engineering Perspectives

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

What Is the Best Treatment for the End-stage Heart Failure Patient With Severe FMR? MitraClip Should Always Be Considered First!

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content